Novartis AG

Dymapak, a global manufacturer specializing in innovative child-resistant packaging solutions for various industries, has introduced a child-resistant Consumer Packaged Goods (CPG) packaging solution.  The so-called 'Squeeze and Turn Tin  represents a significant leap forward in...

Things are starting to heat up in the already hot pharmaceutical sector – especially as it relates to mergers and acquisitions. Only days after Onyx Pharmaceuticals (NASDAQ: ONXX) said it rejected an $8.7 billion buyout offer from Amgen (NASDAQ: AMGN), according to Reuters, the company has...

It’s a simple matter of math. The more diseases there are to treat, the more profit there is to be made – by drug companies that produce the medicines designed to treat those diseases. The Wall Street Journal reported Wednesday that the 5th edition of the Diagnostic and Statistic Manual of...

It’s a sign of the times in health care. If you can’t generate growth, buy it. The New York Times sounded that familiar theme in reporting the pending acquisition Monday of Rochester, N ew York-based Bausch & Lomb by Canadian drugmaker Valeant Pharmaceuticals (NYSE: VRX). J. Michael...

Novartis AG (NYSE: NVS) reported after the close today, November 3rd The New England Journal of Medicine published a study which found patients taking Afinitor tablets saw a decrease in the size of their subependymal giant cell astrocytoma. Astrocytoma's are a benign brain tumor associated with TB...

S&P Downgraded Novartis AG (NYSE: NVS) From Buy to Hold, yesterday. The price target was cut from 66 to 60 on the European traded shares. There was no equivalent price target given for the NY traded shares, as the report came from S&P Europe. Here are a few quotes from the report: “...

Biotech company Human Genome Sciences, Inc. (Nasdaq: HGSI) reported that a study has showed that a monthly dose of its drug Zalbin to treat hepatitus C is just as effective as the current weekly treatment. Human Genome Sciences is working with Novartis AG (NYSE: NVS) on the drug, with Novartis AG...